apceth's Ground-Breaking First-In-Man, First-In-Class Clinical Trial in Oncology with Genetically Modified Mesenchymal Stem Cells Is Now Enrolling

Munich, Germany, (PresseBox) - As a world first, apceth announced today that the TREAT ME Phase I/II clinical trial for patients suffering from advanced adenocarcinoma of the gastro-intestinal tract has commenced. This is the first clinical trial world-wide with genetically-modified mesenchymal stromal cells (MSCs).

This innovative next-generation MSC therapy is based on cells harvested from the patient's own (autologous) bone marrow, which are processed, genetically modified and re-infused into the patient. The cells specifically target the tumor, or its metastases, where the cytotoxic gene product is selectively activated, increasing local efficacy with reduced systemic toxicity, one of the main problems of systemic chemotherapy. This unique principle is also applicable to other cancer types. apceth intends to advance this treatment to an off-the-shelf product where cells obtained for healthy donors will be used to treat multiple patients.

"This is an important milestone for all of us at apceth who strive to produce truly innovative products that make a real difference to patients" said apceth's CEO, Dr Christine Guenther. "We are the first to use next-generation MSC-based therapies in the clinic and this sets us apart from the competition. This is a platform technology that carries significant potential and represents the future of cell therapies".

Apceth GmbH und Co. KG

apceth is a leading European pioneer in the development, GMP manufacturing and clinical implementation of innovative (stem) cell-based therapies, for the treatment of life threatening diseases. It combines the principles of stem cell biology with groundbreaking technologies, applying the highest standards for GMP manufacturing, safety regulations and quality control according to the European Regulation for "Advanced Therapy Medicinal Products" (ATMPs). The company was founded in 2007 and is privately owned by its founders and private investors.

apceth is pleased to offer GMP contract manufacturing services for ATMPs, to pharma and biopharmaceutical partners.

Press releases you might also be interested in

Weitere Informationen zum Thema "Medizintechnik":

KI im Unternehmen: das Für und Wider

Auf der ei­nen Sei­te er­leich­tert der Ein­satz von Künst­li­cher In­tel­li­genz (KI) den Ar­beit­sall­tag, stei­gert die Ef­fi­zi­enz und führt zu ei­ner bes­se­ren Kun­den­bin­dung. Für Un­ter­neh­men er­ge­ben sich je­doch auch neue Scha­den- und Haf­tungss­ze­na­ri­en.

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.